John Gerich

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. ncbi DPP-4 inhibitors: what may be the clinical differentiators?
    John Gerich
    University of Rochester School of Medicine, Rochester, NY 14642, USA
    Diabetes Res Clin Pract 90:131-40. 2010
  2. ncbi Relative importance of liver, kidney, and substrates in epinephrine-induced increased gluconeogenesis in humans
    Christian Meyer
    Department of Medicine, University of Roichester School of Medicine, Rochester, NY 14642, USA
    Am J Physiol Endocrinol Metab 285:E819-26. 2003
  3. ncbi Fluctuation of serum basal insulin levels following single and multiple dosing of insulin glargine
    John Gerich
    University of Rochester Medical Center, Rochester, New York, USA
    Diabetes Technol Ther 8:237-43. 2006
  4. ncbi Exogenous insulin replacement in type 2 diabetes reverses excessive hepatic glucose release, but not excessive renal glucose release and impaired free fatty acid clearance
    Hans J Woerle
    Department of Medicine, University of Rochester School of Medicine, Rochester, NY, USA
    Metabolism 51:1494-500. 2002

Collaborators

Detail Information

Publications4

  1. ncbi DPP-4 inhibitors: what may be the clinical differentiators?
    John Gerich
    University of Rochester School of Medicine, Rochester, NY 14642, USA
    Diabetes Res Clin Pract 90:131-40. 2010
    ..This review offers an overview of DPP-4 inhibitors in T2DM and suggests some characteristics that may provide clinically relevant differentiators within this class...
  2. ncbi Relative importance of liver, kidney, and substrates in epinephrine-induced increased gluconeogenesis in humans
    Christian Meyer
    Department of Medicine, University of Roichester School of Medicine, Rochester, NY 14642, USA
    Am J Physiol Endocrinol Metab 285:E819-26. 2003
    ....
  3. ncbi Fluctuation of serum basal insulin levels following single and multiple dosing of insulin glargine
    John Gerich
    University of Rochester Medical Center, Rochester, New York, USA
    Diabetes Technol Ther 8:237-43. 2006
    ..This lower fluctuation of glargine over NPH or ultralente can help to reduce hyper- or hypoglycemia risks associated with insulin therapy and accordingly encourage achievement of better blood glucose control...
  4. ncbi Exogenous insulin replacement in type 2 diabetes reverses excessive hepatic glucose release, but not excessive renal glucose release and impaired free fatty acid clearance
    Hans J Woerle
    Department of Medicine, University of Rochester School of Medicine, Rochester, NY, USA
    Metabolism 51:1494-500. 2002
    ..04) and was similar to DM(-) (7.3 +/- 0.5 mL x kg(-1) x min(-1), P >.9). We conclude that in contrast to the excessive HGR, excessive RGR and impaired FFA clearance are not corrected by acute exogenous insulin replacement...